China Resources Zizhu Epalrestat Tablets has been approved by the National Food and Drug Administration's "Drug Supplementary Application Approval Notice" (Notice No.: Approval No. 2023B02023), and has passed the evaluation of the quality and efficacy consistency of generic drugs.

The domestic market size of Epalrestat Tablets exceeds 1 billion yuan. It has been sold over 100 million yuan by CRZP, which has become another most competitive product in 2022. At the same time, the process and packaging form of the API were optimized and improved, which creating favorable conditions for further expanding the market and participating in the upcoming National centralized procurement competition.